February 24, 2026

The Potential of Fasting and Diet in the Future of Medicine

May 19, 2025

Cerecin CEO Charles Stacey: ‘Oral Alzheimer’s drug to launch by 2029’

April 8, 2025

Arche Investment, a Reyon Pharm subsidiary, begins IPO for Cerecin as bio sector investment results become tangible

March 10, 2025

BNK and Hanwha Investment & Securities to invest up to KRW 32 billion in Cerecin pre-IPO

March 7, 2025

Cerecin, a Nestlé Group affiliate, plans pre-IPO funding of up to KRW 40 billion

02 December 2024

Cerecin Signs an MOU with Oncogen

29 September 2024

Drinkable Dementia Medication Phase 3… Knocks on KOSDAQ Listing Next Year

2 July 2024

What choices do VC’s make when the bio industry is in a deep freeze?

29 November 2023

Leaders in Innovative Brain Health

4 October 2022

Cerecin Closes Series IIB Financing

May 27, 2021

Interview: Cerecin’s company progress and expansion into migraine and infantile spasms

February 1, 2019

Interview: AD is the largest unmet clinical need

October 24, 2018

Interview: Brains and medicine

May 5, 2016

Nestlé Wants to Sell You Both Sugary Snacks and Diabetes Pills

July 2, 2015

Accera Hoping for an Alzheimer’s Breakthrough

June 24, 2015

Accera Pivots From Medical Foods to Potential Drug for Alzheimer’s

Ketogenic Drug Tricaprilin (CER-0001) for the Treatment of Refractory Infantile Epileptic Spasms

Cantillon M, Chen S, McIntyre N, Henderson ST, Riney K, Chan DWS, Lawson J. and Chow L (2026)

Tricaprilin (CER-0001) for the preventive treatment of migraine: A phase 2 randomised, double-blind, placebo-controlled pilot study

Lilian Chow, Julia Presanis, Nikki McIntyre, Samuel Henderson, Mark Bloch, Elspeth Hutton, Marc Cantillon 15 September 2024

The role and mechanism of metabolic dysfunction in the development of neurodegenerative disease

The role and mechanism of metabolic dysfunction in the development of neurodegenerative disease 12 February 2024

Tricaprilin, an Investigational Ketogenic Drug in Refractory Infantile Spasms

Marc Cantillon MD, John A Lawson BMed Phd, Eric Kossoff MD, Nikki McIntyre MSc, Samuel Henderson PhD and Lilian Chow IEC 2023

Metabolic Mechanism in Migraine: Tricaprilin, a Ketogenic Agent

Lilian Chow, Julia Presanis DPhil, Nikki McIntyre, Samuel Henderson PhD and Marc Cantillon MD American Headache Society Meeting 2023

Application of FibroScan for hepatic safety monitoring in early clinical studies

Sabina Paglialunga, PhD, Terry O’Reilly, MD CPI, Samuel Henderson, PhD, Bruce H Morimoto, PhD, Lilian Chow, MRDM, Nor Rahimah binte Ramli, Lars Nelleman, MD, Judith Walker, MD 2021 ACCP Virtual Annual Meeting

Administering tricaprilin after a meal optimises bioavailability and minimises adverse events

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Bruce Morimoto, PhD Clinical Trials on Alzheimer’s Disease 2020

Tricaprilin shows similar PK, safety and tolerability in Caucasians and Chinese

Bruce H. Morimoto, PhD; Lilian Chow, MRDM; Lars Nelleman,MD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

An evidence-based risk-mitigation approach to study design in APOE4(-) mild to moderate AD

Judith Anne Walker, MD; Lars Nelleman,MD; Bruce H Morimoto, PhD; Lilian Chow, MRDM Clinical Trials on Alzheimer’s Disease 2020

Novel formulation AC-SD-03 of tricaprilin leads to excellent PK and safety in doses up to 30g BID

Lilian Chow, MRDM; Lars Nelleman, MD; Bruce H. Morimoto, PhD; Judith Anne Walker, MD Clinical Trials on Alzheimer’s Disease 2020

Development of tricaprilin, a ketogenic drug for Alzheimer's disease

Judith Anne Walker, MD; Lars Nelleman,MD; Lilian Chow, MRDM; Samuel T Henderson, PhD Alzheimer's Association International Conference 2020

The rat as a model for CER-0001 formulation development

Samuel T Henderson, PhD, Ameet Ambarkhane PhD, Bruce Morimoto, PhD, and Judith Walker, MD Alzheimer's Association International Conference 2020

A Review of Ketogenic Therapies for Alzheimer’s Disease

S. Henderson Metabolic Health Summit 2019